Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus XELOX as neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma
ChiCTR2500114611Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Pathological Complete Response Rate. Started Dec 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500114611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114611.